Logo

BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate-548 Study for Patients Newly Diagnosed with MGMT-Methylated Glioblastoma Multiforme

Share this

BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate-548 Study for Patients Newly Diagnosed with MGMT-Methylated Glioblastoma Multiforme

Shots:

  • The P-III CheckMate-548 (NCT02667587) study involves assesing of Opdivo + SoC (temozolomide & radiation therapy) vs SoC monothx in patients newly diagnosed GBM that is MGMT-methylated- with its 1EP as PFS per blinded independent central review (BICR) & OS and 2EPs as investigator assess PFS & OS rate ~2yrs.
  • The study resulted in unmet one of its 1EP showing no improvement in PFS for patients
  • Opdivo is a PD-1 immune checkpoint inhibitor targeted to harness body’s own immune system further restoring anti-immune response and is approved in 65+ countries including the US- EU- Japan and China

Click here to read full press release/ article

Ref: Bristol-Myers Squibb | Image: BMS 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions